Noven Therapeutics
As of the edition of 20 October 2026, Noven Therapeutics runs 8 drugs, 6 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 6 |
| Status not established | 2 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Lidocaine | none listed | 2 |
| Methylphenidate | none listed | 11 |
| Estradiol | Ends 2032 (patent) | 6 |
| Paroxetine | none listed | 1 |
| Lithium carbonate | none listed | 3 |
| Dextroamphetamine | none listed | 3 |
A route B row is one company at one target.
Where its trials are
- Bones, joints and muscles: 1 trials led